Table 1.

Demographics.

Schizophrenia	n = 64 (90.1%)
Schizoaffective disorder	n = 7 (9.9%)
Male	n = 48 (67.6%)
Female	n = 23 (32.4%)
Mean age	29.8 (±8.6) years
Mean years of education	13.9 (±2.2) years
Mean duration of illness	8.1 (±7.6) years
Mean age of first psychotic episode	21.9 (±4.9) years
Treatment resistance	n = 34
Family SES	48.0 (±12.2)
Nonsmokers	n = 38 (53.5%)
Smokers	n = 33 (46.5%)
Mean chlorpromazine equivalents	304.7 (±160.6) mg
Haloperidol	n = 4 (5.6%)
Aripiprazole	n = 10 (14.1%)
Olanzapine	n = 25 (35.2%)
Quetiapine	n = 6 (8.5%)
Risperidone	n = 21 (29.6%)
Ziprasidone	n = 3 (4.2%)
Other antipsychotic medication	n = 2 (2.8%)
Active arm first	n = 28 (39.4%)
Active arm second	n = 43 (60.6%)

Demographic information for the 71 participants in the study including diagnosis, gender, age (±1 STD), race, years of education (±1 STD), duration of illness (±1 STD), age of first psychotic episode (±1 STD), treatment resistance (clozapine trial or at least 2 antipsychotic medication failures), family socioeconomic status (SES, ±1 STD) as calculated by using the Hollingshead four-factor index (Hollingshead, 1975), and current smoking (tobacco) status. Also included are chlorpromazine equivalents (using Woods's calculations except for molindone for which psychopharmacopeia.com was used; ±1STD) for medication used during the active arm (Woods, 2003), medication patients were on during the active arm, and which arm was active for patients. “Other antipsychotic medication” category includes molindone and trifluoperazine.